<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02342275</url>
  </required_header>
  <id_info>
    <org_study_id>2014-229</org_study_id>
    <nct_id>NCT02342275</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma</brief_title>
  <official_title>Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>West China Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of orally administered propranolol
      versus atenolol in the treatment of potentially disfiguring or functionally threatening IHs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently, propranolol is the preferred treatment for problematic proliferating infantile
      hemangiomas (IHs). Although propranolol is clearly efficacious, rare side effects, such as
      hypoglycemia, may be life-threatening. The possibility of propranolol resistance and
      treatment failure is also important, and highlights the need for employing more established
      techniques in certain cases.

      Nonselective β-adrenergic antagonists, such as propranolol and timolol, are competitive
      antagonists of catecholamines at the β1- and β2-adrenergic receptors (β-ARs). β2-AR blockade
      may result in hypoglycemia as a result of decreased glycogenolysis, gluconeogenesis, and
      lipolysis. Moreover, bronchial hyperreactivity is a direct effect of nonselective β-blockers,
      resulting in bronchospasms due to pulmonic β2-AR blockade. A solution to minimize many of the
      side effects of nonselective β-blocker therapy may be the use of more selective β1-blockers
      such as metoprolol or atenolol, which, at low dosages, have little β2 activity.
      Unfortunately, there is a paucity of clinical data comparing the efficacy of selective and
      non-selective β-blocker. Furthermore, because of the broad heterogeneity of IH (e.g.,
      proliferating versus involuting), confounding with other pharmacologic exposures (e.g.,
      corticosteroids), associated complications (e.g., ulceration) and comorbid medical anomalies
      (e.g., PHACE) that can influence efficiency after IH treatment, observational studies are
      unable to definitively establish the clinical utility of β-blockers in IH. Thus, questions
      regarding the efficacy of the subtypes of β-blockers must be answered in randomized
      controlled trials, which may provide the only way to overcome the selection and ascertainment
      bias.

      The purpose of this study is to compare the efficacy of orally administered propranolol
      versus atenolol in the treatment of potentially disfiguring or functionally threatening IHs.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The color (redness or blueness) and size of IH</measure>
    <time_frame>24 weeks</time_frame>
    <description>Response to therapy was measured by blinded volume estimation at weeks 0, 4, 8, 12, 16, 20, and 24 by using serial hemispheric measurements of tumor volume. Photographs of the IHs were taken at weeks 0, 1, 4, 12, and 24 by a medical photographer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events (e.g. hypotension, hypoglycemia, sleep disturbance, cool or mottled extremities, diarrhea, etc.) collected by investigator and reported by parents.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular examinations, including blood pressure, heart rate and electrocardiogram were performed at weeks 0, 1, 4, 12, and 24.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood glucose was measured at weeks 0, 1, 4, 12, and 24.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurodevelopment</measure>
    <time_frame>12 months</time_frame>
    <description>At one year of age, children were tested using the Gesell Developmental Schedules (GDS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QOL)</measure>
    <time_frame>24 weeks</time_frame>
    <description>The QOL instrument for IH (IH-QOL), Pediatric Quality of Life Inventory (PedsQLTM) 4.0 Genetic Core Infant Scales (GCIS), PedsQLTM 4.0 Family Impact Module (FIM) and PedsQLTM Family Information Form (FIF) were used.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Hemangioma</condition>
  <arm_group>
    <arm_group_label>Propranolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Propranolol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atenolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atenolol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>Initiated at a dosage of 1 mg/kg per day divided 3 times daily for 1 week, and then increased to 2 mg/kg per day divided 3 times daily from weeks 2 to 24.</description>
    <arm_group_label>Propranolol</arm_group_label>
    <other_name>Oral propranolol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atenolol</intervention_name>
    <description>Initiated at a dosage of 0.5 mg/kg per day in a single dose for 1 week, and then increased to 1 mg/kg per day in a single dose from weeks 2 to 24.</description>
    <arm_group_label>Atenolol</arm_group_label>
    <other_name>Oral atenolol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients younger than 24 weeks.

          -  Presenting a hemangioma with the following characteristics:

          -  Subcutaneous and/or cutaneous

          -  Minimum diameter of 1.5 cm on face, 3 cm outside face and 1.5 cm if it is ulcerated.

          -  Consent of both parents (or the person having parental authority in families)

        Exclusion Criteria:

          -  Infant presenting contraindications for the administration of propranolol or atenolol.

          -  Hemangioma has been previous treated with corticosteroids, laser, cryotherapy, or only
             other treatments.

          -  Patients with an inability to participate or to follow the study treatment and
             assessment plan.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>24 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi Ji, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yi Ji, MD, PhD</last_name>
    <phone>+86 02885423453</phone>
    <email>jijiyuanyuan@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi Ji, MD, PhD</last_name>
      <phone>+86 28 85423453</phone>
      <email>jijiyuanyuan@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Siyuan Chen, MD, PhD</last_name>
      <phone>+86 28 85423460</phone>
      <email>siy_chen@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yi Ji, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bo Xiang, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhicheng Xu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fuyu Li, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiaoping Jiang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lin Zhong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Ji Y, Chen S, Xu C, Li L, Xiang B. The use of propranolol in the treatment of infantile haemangiomas: an update on potential mechanisms of action. Br J Dermatol. 2015 Jan;172(1):24-32. doi: 10.1111/bjd.13388. Epub 2014 Dec 17. Review.</citation>
    <PMID>25196392</PMID>
  </reference>
  <reference>
    <citation>Ji Y, Chen S, Li K, Li L, Xu C, Xiang B. Signaling pathways in the development of infantile hemangioma. J Hematol Oncol. 2014 Jan 31;7:13. doi: 10.1186/1756-8722-7-13. Review.</citation>
    <PMID>24479731</PMID>
  </reference>
  <reference>
    <citation>Ji Y, Chen S, Li K, Xiao X, Zheng S. Propranolol: a novel antihemangioma agent with multiple potential mechanisms of action. Ann Surg. 2015 Feb;261(2):e52-3. doi: 10.1097/SLA.0000000000000450.</citation>
    <PMID>24374526</PMID>
  </reference>
  <reference>
    <citation>Ji Y, Chen S, Li K, Xiao X, Xu T, Zheng S. Upregulated autocrine vascular endothelial growth factor (VEGF)/VEGF receptor-2 loop prevents apoptosis in haemangioma-derived endothelial cells. Br J Dermatol. 2014 Jan;170(1):78-86. doi: 10.1111/bjd.12592.</citation>
    <PMID>24033364</PMID>
  </reference>
  <reference>
    <citation>de Graaf M, Raphael MF, Breugem CC, Knol MJ, Bruijnzeel-Koomen CA, Kon M, Breur JM, Pasmans SG. Treatment of infantile haemangiomas with atenolol: comparison with a historical propranolol group. J Plast Reconstr Aesthet Surg. 2013 Dec;66(12):1732-40. doi: 10.1016/j.bjps.2013.07.035. Epub 2013 Sep 4.</citation>
    <PMID>24011909</PMID>
  </reference>
  <reference>
    <citation>Raphaël MF, de Graaf M, Breugem CC, Pasmans SG, Breur JM. Atenolol: a promising alternative to propranolol for the treatment of hemangiomas. J Am Acad Dermatol. 2011 Aug;65(2):420-1. doi: 10.1016/j.jaad.2010.11.056.</citation>
    <PMID>21763565</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2015</study_first_submitted>
  <study_first_submitted_qc>January 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2015</study_first_posted>
  <last_update_submitted>October 5, 2017</last_update_submitted>
  <last_update_submitted_qc>October 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West China Hospital</investigator_affiliation>
    <investigator_full_name>Yi Ji</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Infantile hemangioma</keyword>
  <keyword>Propranolol</keyword>
  <keyword>Atenolol</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemangioma</mesh_term>
    <mesh_term>Hemangioma, Capillary</mesh_term>
    <mesh_term>Port-Wine Stain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
    <mesh_term>Atenolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

